3D vs 2D laparoscopic radical prostatectomy in organ-confined prostate cancer: comparison of operative data and pentafecta rates: a single cohort study

Pierluigi Bove*, Valerio Iacovelli, Francesco Celestino, Francesco De Carlo, Giuseppe Vespasiani and Enrico Finazzi Agrò

Abstract

Background: Currently, men are younger at the time of diagnosis of prostate cancer and more interested in less invasive surgical approaches (traditional laparoscopy, 3D-laparoscopy, robotics). Outcomes of continence, erectile function, cancer cure, positive surgical margins and complication are well collected in the pentafecta rate. However, no comparative studies between 4th generation 3D-HD vision system laparoscopy and standard bi-dimensional laparoscopy have been reported. This study aimed to compare the operative, perioperative data and pentafecta rates between 2D and 3D laparoscopic radical prostatectomy (LRP) and to identify the actual role of 3D LRP in urology.

Methods: From October 2012 to July 2013, 86 patients with clinically localized prostate cancer [PCa: age ≤ 70 years, prostate-specific antigen (PSA) ≤ 10 ng/ml, biopsy Gleason score ≤ 7] underwent laparoscopic extraperitoneal radical prostatectomy (LERP) and were followed for approximately 14 months (range 12–25). Patients were selected for inclusion via hospital record data, and divided into two groups. Their patient records were then analyzed. Patients were randomized into two groups: the former 2D-LERP (43 pts) operated with the use of 2D-HD camera; the latter 3D-LERP (43 pts) operated with the use of a 3D-HD 4th generation view system. The operative and perioperative data and the pentafecta rates between 2D-LERP and 3D-LERP were compared.

Results: The overall pentafecta rates at 3 months were 47.4% and 49.6% in the 2D- and 3D-LERP group respectively. The pentafecta rate at 12 months was 62.7% and 67% for each group respectively. 4th generation 3D-HD vision system provides advantages over standard bi-dimensional view with regard to intraoperative steps. Our data suggest a trend of improvement in intraoperative blood loss and postoperative recovery of continence with the respect of the oncological safety.

Conclusions: Use of the 3D technology by a single surgeon significantly enhances the possibility of achieving better intraoperative results and pentafecta in all patients undergoing LERP. Potency was the most difficult outcome to reach after surgery, and it was the main factor leading to pentafecta failure. Nevertheless, further studies are necessary to better comprehend the role of 3D-LERP in modern urology.

Keywords: Laparoscopic radical prostatectomy, Pentafecta, 3D laparoscopy, Prostatectomy

* Correspondence: pierluigi.bove@uniroma2.it
Department of Urology, Tor Vergata University of Rome, Vle Oxford 81, 00133 Rome, Italy

© 2015 Bove et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Prostate cancer is the most common tumor in people aged over 50 and is the second leading cause of cancer death in Europe and in the United States. Worldwide, nearly 900,000 men were estimated to have been diagnosed with prostate cancer during 2008 and 258,000 men died for this reason [1]. Incidence in Western countries is higher than in less developed ones where it is slowly increasing. Furthermore, there were recent significant decreases in prostate cancer mortality in Europe and in the United States. In contrast, mortality rates have increased in other countries [2,3]. Decreasing mortality rates is mainly due to earlier diagnosis and improved treatment.

Laparoscopic radical prostatectomy (LRP) has become an established treatment for organ confined prostate cancer and is increasingly performed at selected centers worldwide even though open radical retropubic prostatectomy (RRP) is widely considered the treatment of choice. For the first time in 1992 Schuessler carried out a LRP in order to transfer the well-known advantages of the laparoscopic technique to the most common open surgical treatment for prostate cancer [4]. Only after years, Guillonneau and Valencien improved the techniques obtaining results similar to those of open surgery but, because of the steep learning curve, laparoscopic radical prostatectomy has slowly risen in popularity [5]. The advent of robotic surgery has further helped to confine laparoscopic surgery to a special niche. Shorter learning curve, three-dimensional view as well as the ease of movement offered by the Da Vinci® operating arms have made robot-assisted laparoscopic prostatectomy (RALP) more reproducible despite the higher costs. So RALP is easier to learn and is now the surgical treatment of choice in most centers of excellence in the United States [6].

Nowadays, laparoscopic surgery could be regenerated by the introduction of a high-resolution three-dimensional view (3D). 3D techniques have been improved in comparison to the first generation of 3D vision system introduced in the 90s and can even replace the classic bi-dimensional view [7]. 3rd-generation three-dimensional view was introduced about 10 years ago but few experiences were reported in literature probably due to some limit of this technique. The use of a quite heavy helmet with a head mounted display caused surgeon fatigue [8,9]. 4th-generation three-dimensional system uses more ergonomic glasses and an innovated technology.

Better knowledge of pelvic anatomy, improvements in surgical technique have led to improved oncological results and reduced adverse functional outcomes. Historically, outcomes of continence, erectile function, and oncologic control were the major surgical achievement and were called ‘trifecta’ outcomes. Nowadays, patients with a diagnosis of prostate cancer are younger, healthier and have higher expectations from the advanced minimally invasive surgical technologies. Hence, the ‘pentafecta’ was proposed as a new method of outcomes analysis by adding early complications and positive surgical margins (PSMs) to trifecta [10]. According to these theories, pentafecta has become a new cornerstone in the analysis of urological surgery results.

In this pilot randomized study, we aim to highlight the differences between the standard two-dimensional (2D) with the 4th-generation three-dimensional view (3D) applied to laparoscopic extraperitoneal radical prostatectomy (LERP) in order to assess if the 3D visualization of the operative field could really improve intraoperative and perioperative steps and the pentafecta outcomes.

Methods
Patients and technologies
From October 2012 to July 2013, all patients with clinical T1c prostate tumor, belonging to low/intermediate D’Amico risk group, were included in the study. 86 consecutive patients, who met these criteria, underwent LERP. Patients were selected for inclusion via hospital record data. The data were collected in a database and retrospectively analyzed. Fondazione PTV – Policlinico Tor Vergata Ethics Committee approved our clinical study and data collection. In accordance with our institution’s Ethics Committee, informed and signed consent was obtained from each patient prior treatment. A statement of ethical approval covered permission to access patient records and use them for study purposes. All patients constituting the cohort had at least 1 yr follow-up.

Patients were randomized into two groups: the former 2D-LERP (43 pts) operated with the use of 2D-HD Storz® camera with a 10 mm 0° laparoscope; the latter 3D-LERP (43 pts) operated with the use of a 3D-HD Viking® camera with a 10 mm and 0° lens double-channel stereolaparoscope. The 3D view is achieved with the help of a 3DHD Viking® screen and with the use of polarized glasses. The glasses are filtered; each lens only lets one direction of light pass through the eye, thus maintaining two perspectives of the image and giving a tridimensional vision.

Procedures: surgery and rehabilitation
All 86 patients were operated by the same surgeon (P.B.) following the same surgical technique of LERP. A 1,5 cm cutaneous incision is made at 1 cm below the inferior margin of the umbilicus and a dilator device is inserted into the preperitoneal space and about 300 ml of air is inflated to develop the space of Retzius (pneumo- Retzius). 4 secondary trocars are then placed under laparoscopic view (2 for each iliac fossa, right and left) in the inverted fan configuration. The endopelvic fascia is
incised on each side and bladder neck is dissected and isolated through the “bladder neck sparing” technique. Once the bladder neck is opened close to the prostate, the posterior lip of the bladder neck is lowered to provide access to the interprostatorectal plane. Vasa deferentes and seminal vesicles are isolated and dissected. Then, prostatic pedicles are incised in an anterograde mode with preservation of the neurovascular bundle when it is indicated. Finally, a meticulous preparation of the urethral stump introduces to the vesicourethral anastomosis which is collected in interrupted sutures [11].

The drainage is left in place until leakage is observed, and normally it is removed on second post-operative day. Urinary fistula is defined as prolonged drainage over postoperative day 10. The catheter is normally removed between 7 and 10 days after surgery; in case of urinary fistula a cystography is carried out on 14th and 21st postoperative day and both drainage and catheter are removed at the complete closure of the anastomosis.

Baseline sexual and urinary functions were assessed before LERP with self-administered, validated questionnaires: the International Index of Erectile Function 6 (IIEF-6) and the Incontinence Quality of Life (I-QoL) [12,13]. Pelvic floor muscles exercises were recommended for all patients immediately after catheter removal in order to facilitate continence recovery. After catheter removal, all patients received phosphodiesterase type 5 (PDE5) inhibitors at least three times a week and began penile rehabilitation no later than three weeks after radical surgery by using intracavernous pharmacotherapy (ICP) with Prostaglandin E1 (alprostadil).

**Operative and perioperative data**
Operative and perioperative data are presented in Table 2. Median OT for 3D-LERP was significantly shorter than that in 2D-LERP (162 versus 241 minutes, p 0.01). Moreover, in the 3D LERP group, median OT for the first 3 cases was significantly longer than the remaining cases due to the initial operator learning curve. Statistically significant differences were also recorded in median AT (24 versus 32 minutes, p 0.03) and median NuS (5.65 versus 6.45, p 0.018). Median EBL did not reach a statistical significance in the two groups with two patients requiring transfusion in the 2D group and 1 patient in the 3D group. No conversion to open surgery was necessary and no complications occurred requiring early re-intervention. Median HS was 7.6 and 5.5 days for the 2D-LERP and 3D-LERP respectively (p = 0.180). Median DD was 5 in the 2D-LERP and 4.5 in the 3D-LERP (p = 0.880).

**Complications**
Complications can be considered as a perioperative outcome. We discussed complications apart from the other perioperative data in order to underline their role in the pentafecta.

Modified Clavien grading system was used to classify complications occurring during the surgical procedure or within 90 days after surgery (early complications) [15]. Twenty-three of 86 patients experienced complications. More specifically, perioperative complications were reported in 15 (34.8%) cases in the 2D-LRP and in 8 (18.6%) cases in the 3D-LRP. 2D-LRP and 3D-LRP complications

**Statistical analysis**
Fisher test was used to analyze non-parametric data as appropriate. Student t-test was used to analyze parametric data such as patients’ characteristics, intra and remaining perioperative data. Results were considered significant if the p value was ≤ 0.05.

**Results**
There were not significant differences between the two groups in terms of age, body mass index (BMI), preoperative PSA level and biopsy Gleason score. Patients’ characteristics are summarized in Table 1.

**Data collection**
Operative and perioperative data. Operative time (OT – from skin to skin closure), anastomosis time (AT – time to complete the anastomosis till the catheter insertion), number of stitches used (NuS), estimated blood loss (EBL) and any intraoperative complication were recorded. Perioperative data include: days of drainage (DD), days of catheterization (DC), hospital stay (HS), pathological staging and complications. Histopathologic staging was performed according to the 2002 TNM system [14].

Pentafecta. The five outcomes included in the analysis of the pentafecta are complications, positive surgical margins (PSMs) and the trifecta outcomes (urinary continence, sexual potency, biochemical recurrence BCR-free survival rates). Pentafecta is achieved if there were no complications, negative surgical margins and if the patient was continent, potent and BCR-free.

**Table 1 Preoperative data**

| Variable              | 2D  | 3D  |
|-----------------------|-----|-----|
| Age, yr, mean         | 60.1| 63.9|
| BMI, mean             | 25.2| 24.6|
| Preoperative PSA value (ng/mL) | 6.7  | 6.2  |
| Biopsy Gleason score  | 6.15| 6.15|
are summarized in Table 3. Minor complications (Clavien grade 1 and 2) represent respectively 80% and 63% for the two groups of all those reported. Major complications (Clavien grade ≥ 3) constituted respectively 20% and 37%. There were no cases of complications graded 4a, 4b and 5 according to the modified Clavien grading system. Data are depicted in Table 3.

**Oncologic outcomes: biochemical recurrence and positive surgical margins**

Oncological results are presented in Tables 4 and 5. The distribution of pathological stage and Gleason score was similar in the 2 groups.

**Table 3 Complications**

| Modified Clavien grading system | 2-D (n = 43) | 3-D (n = 43) |
|---------------------------------|--------------|--------------|
| **Grade 1**                     |              |              |
| Penis and scrotum edema         | (n = 7)      | (n = 5)      |
| Hematuria (n = 1)               | 0            | 0            |
| bladder catheter exchange (n = 1) | 0            | 0            |
| **Grade 2**                     |              |              |
| transfusions (n = 2)            | 0            | 0            |
| Epididymitis (n = 1)            |              |              |
| **Grade 3a**                    | AUR (n = 1)  | AUR (n = 1)  |
| Anastomotic stenosis (n = 2)    | Anastomotic stenosis (n = 1) |
| **Grade 3b**                    | 0            | Urinary fistula (n = 1) |
| **Grade 4a-b/5**                | 34.8% (15)   | 18.6% (8)    |
| **Total (%)**                   | 34.8% (15)   | 18.6% (8)    |

| Pathological stage | 2-D (n = 43) | 3-D (n = 43) |
|--------------------|--------------|--------------|
| pT2a               | 5 (12%)      | 6 (14%)      |
| pT2b               | 3 (7%)       | 3 (7%)       |
| pT2c               | 25 (58%)     | 23 (54%)     |
| pT3a               | 7 (16%)      | 8 (18%)      |
| pT3b               | 3 (7%)       | 3 (7%)       |

The overall PSM rate was 9% in the 2D-LERP and 4% in the 3D-LERP. When stratified by pathological stage, PSM rate was significantly different in pT2c/pT3 disease between groups (halved in the 3D-LERP compared with the 2D-LRP group).

BCR was defined as two consecutive prostate-specific antigen (PSA) levels of >0.2 ng/ml [16]. The overall BCR-free rate at 3 months was 93% (2D-LERP, 40 patients) and 95% (3D-LERP, 41 patients). Reassessed at 12 months, the overall BCR-free rate was 88% (2D-LERP, 38 patients) and 91% (3D-LERP, 39 patients). Patients with recurrences underwent further salvage therapy with either radiation and/or hormonal treatment. Aligned with the literature data, 25% of the patients with BCR had PSMs.

**Table 4 Histopathologic data**

| Pathologic stage | 2-D (n = 43) | 3-D (n = 43) |
|------------------|--------------|--------------|
| pT2a             | 5 (12%)      | 6 (14%)      |
| pT2b             | 3 (7%)       | 3 (7%)       |
| pT2c             | 25 (58%)     | 23 (54%)     |
| pT3a             | 7 (16%)      | 8 (18%)      |
| pT3b             | 3 (7%)       | 3 (7%)       |

**Urinary continence**

According to the European Association of Urology Guidelines (EAU Guidelines, 2013), urinary incontinence represents a postoperative complication that persists after 1 year in 7.7% of patients who underwent radical prostatectomy [17]. The American Urological Association Guidelines (AUA Guidelines, 2007 updated in 2011)

| Table 5 Oncological results | 2-D (n = 43) | 3-D (n = 43) |
|-----------------------------|--------------|--------------|
| Positive surgical margin    | 9% (4)       | 4% (2)       |
| pT2c                        | 2/25         | 1/23         |
| pT3                         | 2/10         | 1/11         |
| BCR-free rate (%)           |              |              |
| 3 months follow-up          | 93% (40)     | 95% (41)     |
| 12 months follow-up         | 88% (38)     | 91% (39)     |
report a rate of postoperative urinary incontinence that ranges between 3% and 74% [18].

Urinary continence was assessed with the self-administered, validated questionnaire Incontinence Quality of Life (I-QoL). The definition of continence was based on a specific question appropriate to reflect the range of incontinence severity: “How many pads per day did you usually use to control urine leakage during the last 4 weeks?”. We considered “dry” patients without any loss of urine (no pads/day) or those who used a safety pad/day.

The overall continence rates did not reach a statistically significant difference although the trend is clearly favorable to the 3D-LERP group (89% and 92% vs 83% and 88% of patients were continent at 3 and 12 month follow-up in the 3D and 2D-LERP group respectively).

I-QoL questionnaire showed a significant quality of life improvement at the first month in the 3D (mean score 90.45) compared to the 2D-LERP group (mean score 81.8) (p = 0.01). These positive results are also confirmed at third (93.3 vs 83.6 - p = 0.01) and twelfth (95.4 vs 88.1 p = 0.03) month follow-up in the 3D compared to the 2D-LERP group respectively. Pre- and postoperative urinary continence data are depicted in Table 6.

Erectile function
It is widely recognized that the preoperative Erectile Function (EF) is an important prognostic factor for erectile dysfunction recovery after radical prostatectomy [19]. Several other factors are predictive for EF recovery after surgery: age, type of surgery, pre- and post-RP libido, adjuvant treatments, comorbidities, urinary continence, availability of a partner and sane mental health. Therefore, it is essential to determine the EF baseline. The International Consultation on Sexual Medicine (ICSM) Committee recommends the use of validated psychometric instruments such as IIEF. In our experience, potency rate has been assessed using the IIEF-6. After surgery, erectile function rehabilitation was recommended for all patients (scheme reported above) in order to preserve the functional smooth muscle tissue of the corpora cavernosa and to avoid the effects of the surgical-related neuroapraxia [20].

Preoperative Potency was defined as the ability to achieve and maintain satisfactory erection for sexual activity or as a score IIEF-6 score ≥ 17 (without pharmacological or mechanical support). Post-operative potency was defined as the ability to achieve and maintain erections firm enough for sexual intercourse in more than 50% of attempts, with or without the use of iPDE5 and with eventual ICP (IIEF-6 score ≥ 17).

Patients were subjected to bilateral or unilateral nerve-sparing surgery (NSS). The overall potency rates were 60% and 67% at 3 months and 67% and 72% at 12 months in the 2D- and 3D-LERP group respectively. Type of surgery, pre-surgical evaluation of erectile function and potency outcomes are summarized in Tables 7 and 8.

Pentafecta outcomes
The overall pentafecta rate at 3 months was 47.4% and 49.6% in the 2D- and 3D-LERP group respectively. The pentafecta rate at 12 months was 62.7% and 67% for each group respectively.

The most common reasons for not achieving the pentafecta were erectile dysfunction (33% and 28% respectively in 2D-LERP and 3D-LERP; trifecta not achieved) and complication rate (34.8% and 18.6%, 2D vs 3D). Furthermore, urinary incontinence (12% and 8%, 2D vs 3D), BCR (12% and 9%, 2D vs 3D) and positive surgical margins (9% and 4%, 2D vs 3D). Results are shown in Table 9.

Discussion
In the past decade, a dramatic shift towards lower-stage tumors has become evident. Currently, men are younger at the time of diagnosis and more interested in less invasive surgical approaches (eg. Laparoscopy, robotics) than they are for the traditional approach [21]. At the same time and more importantly, normal continence and preserving sexual function are fundamental but not the only primary goals of radical prostatectomy. Patients want to know if the treatment option will render them cancer free with a minimum of complications and the shortest possible convalescence time while preserving continence and potency [10].

These observations highlight two main topics: on one hand, the possibility of considering a minimally invasive surgical approach with its innovative technical characteristics

### Table 6 Continence data

| Pad system | 2-D | 3-D |
|------------|-----|-----|
| Pre-operative | 100% (43) | 100% (43) |
| 3 months follow-up | 83% (36) | 89% (38) |
| 12 months follow-up | 88% (38) | 92% (40) |
| I-QoL | 2-D | 3-D |
| 3 months follow-up | 83,6 | 93,3 |
| 12 months follow-up | 88,1 | 95,4 |

### Table 7 Potency surgical approach

| Nerve sparing surgery | 2-D | 3-D |
|-----------------------|-----|-----|
| Monolateral | 42% (18) | 37% (16) |
| Bilateral | 58% (25) | 63% (27) |
operation. Even if the experienced surgeon is able to perform with a success rate of 86% (37) and 88% (38) as reported by et al. BMC Urology 2013.

Table 8 Potency data

| Erectile Function (≥ 17) | 2-D | 3-D |
|-------------------------|-----|-----|
| Pre-operative            | n = 43 | n = 43 |
| 3 months follow-up       | 86% (37) | 88% (38) |
| 12 months follow-up      | 67% (29) | 72% (31) |

Table 9 Variables comprising the pentafecta success rates at 12 mo

| Variable | 2D LERP Patients | % | 3D LERP Patients | % |
|----------|------------------|---|------------------|---|
| Complication | 28/43 | 65 | 35/43 | 81 |
| PSM       | 39/43 | 91 | 41/43 | 96 |
| BCR-free rate | 38/43 | 88 | 39/43 | 91 |
| Continence | 38/43 | 88 | 40/43 | 92 |
| Potency   | 29/43 | 67 | 31/43 | 72 |
| Pentafecta | 27/43 | 62,7 | 29/43 | 67 |

every time that it is possible and, on the other hand, the necessity of adopting a more comprehensive method of reporting peri- and post-operative outcomes.

By adopting the laparoscopic technique with adherence to established oncological principles, the aim is to duplicate the open surgical method in its entirety. LRP has slowly risen in popularity and has become, in some centers, the surgical approach of choice for the treatment of localized prostate cancer for its advantages. Lower blood loss and transfusion rate associated with the laparoscopic approach together with shorter hospital stay, reduced catheterization time, better pain control and faster return to everyday activities seem to be the most encouraging improvements obtained [22].

Unfortunately, classic laparoscopic surgery is limited by a two-dimensional vision that does not allow perception of the operative field as in open surgery. The lack of depth perception has repercussions both on the learning curve, which still constitutes a major obstacle to the development of laparoscopy [23], and in the possibility for the surgeon to maneuver the instruments with an accuracy comparable to that which would occur in the same “open” operation. Even if the experienced surgeon is able over time to regain some vision of depth, this will never be optimal [24].

For this reason and through the increasing popularity of laparoscopy, a three-dimensional display system was introduced in the early 90s, with the expectation that this technique could make laparoscopic interventions safer and faster [23]. Up to now, just a few studies on three-dimensional laparoscopy have been written without any definite conclusion about its utility. Some articles describe better results with 3D laparoscopic technique than with the 2D system both in surgical training exercises and in different surgical procedures. Exercises like linear cutting and suturing, curved cutting and suturing, tubular suturing and dorsal vein complex suturing simulation have been performed and it has been suggested that the new-generation 3D system could be helpful in laparoscopy [25-27].

In the 90s, comparative studies were organized to evaluate the improvement and superiority of vision between traditional 2D and 3D system (3rd generation) in terms of dissection of the kidney, securing of the renal vessels and laparoscopic suturing, but the Authors found no differences between the two vision systems, either with respect to the accuracy and speed of surgical execution, nor as regards to the learning curve [28-32]. Gynecologists and general surgeons have described similar studies in the field of 3D laparoscopic surgery with discordant conclusions [33-35].

Robotic surgery had a great benefit from the three-dimensional view. The advent of Da Vinci® has further helped to confine laparoscopic prostatectomy to a special niche. Shorter learning curve, three-dimensional view as well as the ease of movement offered by the operating arms, makes robot-assisted laparoscopic prostatectomy (RALP) more reproducible despite the higher costs. This way, Robertson et al. recently underlined that RALP is easier to learn and is now the surgical treatment of choice in most centers of excellence in the United States [22].

This is the first study reported in urologic literature that aims to establish, after twenty years since the first 3D model was introduced, the utility of the 4th generation 3D vision system during LERP in terms of feasibility and potential advantages over the 2D vision system regarding operative and perioperative data and the pentafecta outcomes. Only one work reported by Good et al. in 2013 analyzed the pentafecta learning curve for laparoscopic radical prostatectomy [36].

Transition from the 2D to 3D vision system, requires an initial period of adaptation. This is demonstrated by longer operative time and the incidence of post-operative urinary fistula that occurred at the very beginning of our experience using the 3D vision system. This short learning curve is related to a new perception of the depth of the operative field that requires a different spatial assessment of instrument positioning rather than an initial difficulty in recognizing anatomical landmarks avoiding possible complications. Once adaptation to 3D view is reached, a more realistic visualization of the surgical field allows greater speed and precision in the movement of the surgical instrument. This translates in a better preparation of the bladder neck and the urethral stamp reducing anastomosis time. Although not resulting in a statistically significant difference, the easy identification of small vessels using the 3D vision may reduce blood loss.
Despite the necessary adaptation from 2D to 3D vision by an expert laparoscopist, on the other hand, the 3D vision may offer significant advantages in teaching laparoscopic skills to inexperienced individuals [37]. Meticulous handling and tissue dissection obtained with the auxilium of the 3D view have allowed earlier continence recovery. This could be mainly related to less trauma and greater sphincteric structures saving [38] as demonstrated by a better I-QoL and a decreased number of pads per day in the 3D LERP Group. One of the operating steps that gets more advantages from the 3D view is the dissection of seminal vesicles, vas deferens and prostatic pedicles. Dissection of these delicate structures makes 3D vision very effective. Basically, these operating stages and their higher accuracy might affect a possible earlier and better recovery of erectile function.

These encouraging results obtained with the 3D vision system were associated with a number of positive surgical margins and post-operative complications comparable in both groups demonstrating a good oncological and functional efficacy. From our point of view, some problems related to the prolonged use of 3D vision such as headaches, fatigue and nausea, already reported in previous studies, have still remained unresolved, but it is not an important limitation to its use [39,40]. Statistically significant differences were recorded for all intraoperative steps and data suggest a trend of improvement in intraoperative blood loss, postoperative recovery of continence and potency with the respect of the oncological safety for the 4th generation 3D-HD vision system of the 3D-LERP over standard bi-dimensional view in 2D-LERP.

One of the advantages of this study is that the comparison between the 2D and 3D surgical procedures was performed by a single surgeon making it more reliable and avoiding possible bias. Despite this fact, the extensive experience of the surgeon may have influenced the results and complication rates of our study and, as a result, the outcomes cannot be generalized.

However, this study has several limitations. First of all, being a pilot study, with a small number of procedures and a relatively short follow-up, it does not allow the definition of the definitive role of this technique. Data analysis was a retrospective. Some data may not reach a statistical significance between groups because the study was not powered to identify these differences; nevertheless, a trend of improvement in surgical and functional outcomes has been shown. Furthermore, we included both bilateral and monolateral NSS procedures. Another limitation is that we did not use the Expanded Prostate Cancer Index Composite (EPIC) questionnaire to better assess urinary symptoms. Finally, the study is limited by the short follow-up, which can affect BCR-free and functional outcomes.

Nowadays, all the laparoscopic prostatectomies in our Department are performed with the auxilium of 3D video system. If these preliminary data will be confirmed by larger follow-up of a greater number of patients, the 4th generation 3D laparoscopy may play an important role in the treatment of prostate cancer.

Conclusions
This preliminary study has shown that 4th generation 3D-HD vision system provides advantages over standard bi-dimensional view with regard to intraoperative steps. Our data suggest a trend of improvement in intraoperative blood loss and early postoperative recovery of continence along with the respect of the oncological safety. Pentafecta has been reached with a higher score for the 3D-HD LERP.

Given the large number of men diagnosed with prostate cancer and the exponential growth of the medical costs on a global level, it would be better that treatment options are not only effective but also less expensive. In this context, the 3D laparoscopy may be an intermediate step between the standard 2D laparoscopy and robot-assisted laparoscopy, allowing the combination of the low cost of the first with the 3D technology of the second. Further studies are necessary to better comprehend the role of 3D-LERP in modern urology.

Abbreviations
LRP: Laparoscopic radical prostatectomy; LERP: Laparoscopic extraperitoneal radical prostatectomy; RRP: Radical retropubic prostatectomy; RALP: Robot-assisted laparoscopic prostatectomy; 3D HD: High-definition three dimensional view; PMs: Positive surgical margins; IIEF 6: International index of erectile function 6; I-QoL: Incontinence quality of life; PDES: Phosphodiesterase type 5; ICP: Intracavernous pharmacotherapy; OT: Operative time; AT: Anastomosis time; Nu&S: Number of stitches; EBL: Estimated blood loss; DD: Days of drainage; DC: Days of catheterization; HS: Hospital stay; BCR: Biochemical recurrence; BMI: Body mass index; EAU: European association on urology; AUA: American urological association; ICSM: International consultation on sexual medicine; NSS: Nerve-sparing surgery; EPIC: Expanded prostate cancer index composite.

Competing interests
The authors declared that they have no competing interests.

Authors’ contributions
PB carried out the surgical procedures and drafted the manuscript. VI carried out the surgical procedures as assistant and participated in the design of the study. FDC collected all the data and performed the statistical analysis. GV carried out the surgical procedures. EFA conceived the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Received: 3 September 2014 Accepted: 9 February 2015
Published online: 21 February 2015

References
1. International Agency for Research on Cancer (IARC) Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 ver. 2.0. Cancer incidence and mortality worldwide: IARC CancerBase No. 10 Lyon: IARC; 2010. Cited 2012 Jul 12. http://globocan.iarc.fr.
2. Center M, Jemal A, Bray F, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.
3. Baade PD, Youlden DR, Knijjink LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53:171–84.

4. Schuessler W, Sculam P, Clayman R, Kavoussi L. Laparoscopic radical prostatectomy: initial short-term experience. Urology. 1997;50:854–7.

5. Guillonneau B, Villanien G. Laparoscopic radical prostatectomy: the Montsouris technique. J Urol. 2000;163:1643–9.

6. Hakimi AA, Feder M, Chavamani R. Minimally invasive approaches to prostate cancer a review of the current literature. Urol J. 2007;4:130–7.

7. Zobel J. Basics of three-dimensional endoscopic vision. Endosc Surg Allied Technol. 1993;1:36–9.

8. Bhayani SB, Andrule GL. Three-dimensional (3D) vision: does it improve laparoscopic skills? an assessment of a 3D head-mounted visualization system. Rev Urol. 2005;7:621–4.

9. Mueller MD, Camartin C, Dreher E, Ha¨nggi W. Three-dimensional laparoscopy gadget or progress? a randomized trial on the efficacy of three-dimensional laparoscopy. Surg Endosc. 1996;13:469–72.

10. Patel VR, Sivaraman A, Coelho RF, Chauhan S, Palmer KJ, Orvieto MA, et al. Pentafecta: a new concept for reporting outcomes of robot-assisted radical prostatectomy. Eur Urol. 2011;59(5):702–7.

11. Bove P, Iacovelli V. Laparoscopic radical prostatectomy. In: Laparoscopy review and current problems. Semin Laparosc Surg. 2001;8:1212.

12. Rosen RC, Cappelleri JC, Gendrano 3rd N. The international index of erectile function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226–44.

13. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology. 1996;47(1):67–71, discussion 71–2.

14. Greene FL, Page DL, Fleming ID, et al. American joint committee on cancer staging manual, ed 6. New York, NY: Springer; 2002. p. 77–87.

15. Dindo D, Demartines N, Clavien P. Classification of surgical complications. Ann Surg. 2004;240:205–13.

16. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer [in Spanish]. Actas Urol Esp. 2009;33:113–26.

17. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:561–71.

18. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.

19. Salonia A, Burnett AL, Grefen M, Montorsi F, et al. Prevention and management of Postprostatectomy sexual dysfunctions. Eur J Surg. 2012;62:261–72.

20. Muhlhal JP et al. Phosphodiesterase type 5 inhibitors in Postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009;55:334–47.

21. Schroock FR, Krupski TL, Sun L, et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2008;54:785–93.

22. Robertson C, Close A, Fraser C, Gurung T, Jia X, Sharma P, et al. Relative effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of localised prostate cancer: a systematic review and mixed treatment comparison meta-analysis. BJU Int. 2013;112(6):798–812.

23. Abdelshahid CS, Eichel L, Lee D, et al. Current trends in urolologic laparoscopic surgery. J Endourol. 2005;19:151–20.

24. Hofmeister J, Frank TG, Cuschieri A, Wade NJ. Perceptual aspects of two dimensional and stereoscopic display techniques in endoscopic surgery: review and current problems. Semin Laparosc Surg. 2001;8:12–24.

25. Patel HRH, Ribal MJ, Arya M, et al. Is it worth revisiting laparoscopic three-dimensional visualization? a validated assessment. Urology. 2007;70:47–9.

26. Badani KK, Bhandari A, Tewari A, et al. Comparison of Two-dimensional and three-dimensional suturing: is there a difference in a robotic surgery setting? J Endourol. 2005;19:1212–5.

27. Peitgen K, Walz MW, Holmberg G, Eigler FW. A prospective randomized experimental evaluation of three-dimensional imaging in laparoscopy. Gastrointest Endosc. 1996;44:262–7.

28. Chiu AW, Babayan RK. Retroperitoneal laparoscopic nephrectomy utilizing three-dimensional camera case report. J Endourol. 1994;8:139–41.

29. Babayan RK, Chiu AW, Este-McDonald J, Birckett DH. The comparison between 2-dimensional and 3-dimensional laparoscopic video systems in a pelvic trainer. J Endourol. 1993;7:5195.

30. McDougall EM, Sobel II, Wolf JS, Nakada SY, Elashry OM, Clayman RV. Comparison of three-dimensional and two-dimensional laparoscopic video systems. J Endourol. 1996;10:571–4.

31. Jones DB, Brewer JD, Soper NJ. The influence of three-dimensional video systems on laparoscopic task performance. Surg Laparosc Endosc. 1996;6:191–7.

32. Chan ACW, Chung SCS, Yim APC, et al. Comparison of two-dimensional vs three-dimensional camera systems in laparoscopic surgery. Surg Endosc. 1997;11:438–40.

33. Wend R, Lehner R, Vty U, Patieksy N, Sevelda P, Hueslein P. Three-dimensional video endoscopy: clinical use in gynaecological laparoscopy. Lancet. 1994;344:1621–2.

34. Hanna GB, Shimi SM, Cuschieri A. Randomized study of the influence of two dimensional –versus three dimensional imaging on performance of laparoscopic cholecystectomy. Lancet. 1998;351:248–51.

35. Hanna GB, Cuschieri A. Influence of two-dimensional and three-dimensional imaging on endoscopic bowel suturing. World J Surg. 2000;24(4):444–8.

36. Good DW, Stewart GD, Slotenburg JU, McMell SA. Analysis of the pentafecta learning curve for laparoscopic radical prostatectomy. World J Urol. 2014;32(5):1225–33.

37. Votanopoulos K, Bruniciardi FC, Thornby J, et al. Impact of three-dimensional vision in laparoscopic training. World J Surg. 2008;32:110–8.

38. Schommer T, Huland H, et al. Full functional-length urethral sphincter preservation during radical prostatectomy. Eur Urol. 2011;60:530–9.

39. Pietrabissa A, Cancello E, Carobbi A, et al. Three-dimensional versus two-dimensional video system for the trained endoscopic surgeon and the beginner. Endosc Surg Allied Technol. 1994;2:315–7.

40. Taffinder N, Smith SGT, Huber J, et al. The effect of a second-generation 3D endoscope on the laparoscopic precision of novices and experienced surgeons. Surg Endosc. 1999;13:1087–92.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit